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Abstract: Coenzyme Q10 (CoQ10), also known as ubiquinone for its presence in all body 
cells, is an essential part of the cell energy-producing system. However, it is also a 
powerful lipophilic antioxidant protecting lipoproteins and cell membranes. Due to these 
two actions, CoQ10 is commonly used in clinical practice in chronic heart failure, male 
infertility, and neurodegenerative disease. However, it is also taken as an anti-aging 
substance by healthy people aiming for long-term neuroprotection and by sportsmen to 
improve endurance. Many hormones are known to be involved in body energy regulation, 
in terms of production, consumption and dissipation, and their influence on CoQ10 body 
content or blood values may represent an important pathophysiological mechanism. We 
summarize the main findings of the literature about the link between hormonal systems and 
circulating CoQ10 levels. In particular the role of thyroid hormones, directly involved in the 
regulation of energy homeostasis, is discussed. There is also a link with gonadal and 
adrenal hormones, partially due to the common biosynthetic pathway with CoQ10, but also 
to the increased oxidative stress found in hypogonadism and hypoadrenalism. 
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1. Introduction 
Coenzyme Q10 (CoQ10) is the predominant form of ubiquinone in man. The name ubiquinone   
(or ubidecarenone) refers to its ubiquitous diffusion in organisms and tissues. It is a key component of 
the ATP-producing oxidative phosphorylation chain, placed in the inner mitochondrial membrane, and 
linking flavoproteins and cytochroms. However, it is also a powerful lipophilic antioxidant, in 
particular in its reduced form, ubiquinol (Figure 1), which represents more than 80% of the total CoQ10 
in human plasma and protects biological membranes and lipoproteins. Furthermore, new roles in 
different cellular functions have been discovered recently, regarding other cell organelles like 
lysosomes, Golgi apparatus and plasmatic membranes [1]. Finally, CoQ10 can participate in many 
aspects of the oxido-reductive control of the cellular signaling pathways, at least via the auto-oxidation 
of semi-quinon which can be a primary source of H2O2 generation [2]. Also CoQ10 involvement in cell 
proliferation was investigated [1], but most data at present concerns its energetic and antioxidant   
roles [3]. CoQ10 levels in biological fluids can be accurately measured by HPLC, with a method 
standardized by the International CoQ10 Association. Furthermore, electrochemical detection   
(HPLC-EC) allows measuring both the reduced (ubiquinol) and oxidized (ubiquinone) forms of   
CoQ10 [4]. The CoQ10 normal value range in human plasma is 0.8–1.2 mg/L. Since CoQ10 in the blood 
stream is prevalently transported in lipoproteins and above all low-density lipoproteins (LDL), CoQ10 
values are commonly normalized for those of cholesterol (nmol/mmol), in order to minimize the 
confounding effect of cholesterol. Systemic hormones are variously involved in the regulation of 
metabolism, and act as a certain modulation on body antioxidant systems, both in physiological and 
pathological conditions, with hormone excess or deficiency [5]. The aim of this paper is to summarize 
the main findings of the literature about the link between hormonal systems and circulating CoQ10 levels. 
Figure 1. Chemical structure of Coenzyme Q10, in its two redox forms. 
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2. CoQ10 Functions 
2.1. Bioenergetical Role of CoQ10 
CoQ10 was initially isolated as a yellow compound in 1957, from beef heart mitochondria by the 
group of Dr. D. Green at the University of Wisconsin. Then, Dr. K. Folkers determined its structure at 
the research laboratories of Merck in New Jersey; it is a moderately large worm shaped lipid molecule 
about 4 nm long, which can be described as: 2,3-dimethoxy-5-methyl-6-decaprenil-1,4-benzoquinone. 
CoQ10 was soon recognized as essential for the bioenergetics of cell respiration and named a coenzyme 
because of its activity in the enzyme systems of mitochondria. The letter Q indicates its quinonic group, 
while 10 are the isoprenoid units in its sidechain. CoQ10 carries hydrogens through the respiratory 
chain catalytic centres in the mitochondrial christae membrane, allowing coupling of the translocation 
of electrons to the translocation of protons, needed for the formation of chemiosmotic gradient for the 
functioning of ATP synthetase. Since CoQ10 affinity for the enzymes it interacts with, is not high 
enough to saturate them at its physiological concentration in the membrane, then the velocity of 
respiratory chain is very sensitive to variations of total CoQ10 or ubiquinole/ubiquinone ratio [6]. This 
concept links together the classical bioenergetic role of CoQ10 and its antioxidant role: any condition of 
increased oxidative stress, with the involvement of CoQ10 as antioxidant, might decrease its 
availability for oxidative phosphorylation (Figure 2). This is also the rationale for the clinical use of 
exogenous CoQ10 in different conditions and diseases. 
Figure 2. Alteration of CoQ10 levels in four “paradigmatic” endocrine disorders. The 
column on the right side refers to the pathophysiological phenomenon that if CoQ10 is involved 
largely as an antioxidant, then its bioenergetical role may be impaired, and vice versa. 
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2.2. CoQ10 and Oxidative Stress 
Oxidative stress is defined as the unbalance between production of free radicals, molecules 
characterized by high chemical reactivity, and antioxidant defenses, in the biological systems. 
Oxidative stress is considered an important basic pathogenetic mechanism in different diseases. CoQ10 
is an important mechanism of defense against oxidative stress. In fact, the most important and studied 
free radicals are reactive oxygen species (ROS), normally produced during oxidative processes of 
energetic substrates in the mitochondrial respiratory chain [7,8]. An increase in ROS production can be 
due to an increase in the electronic flow in the respiratory chain, resulting from an augmented 
energetic demand or an augmented disposal of substrates [9]. In leukocytes as well as many other 
cytotypes (endothelial and mesangial cells, fibroblasts, thyreocytes, oocytes, Leydig cells, adipocytes, 
Epstein-Barr and neoplastic cells) ROS generation was shown to have a positive pathophysiologic role, 
different from respiratory burst [10]. However an uncontrolled production of free radicals was linked 
to many pathologic events, such as rheumatoid arthritis and myocardial infarction, and in general ROS 
damage occurs in inflamed tissues, characterized from cellular lysis and intracellular content release. 
Moreover, in diabetes mellitus, oxidation, accompanying non-enzymatic glycation, supports the 
formation of irreversible chemical modifications on proteins and other kinds of molecules. The 
formation of these glycoxidation products depends not only on the relative glucose concentrations, but 
also on the local oxidative environment. On the other hand, in diabetic patients antioxidant capacity is 
decreased, finally resulting in an increased susceptibility to oxidative stress [11].  
It is possible to characterize different cellular defensive mechanisms against the free radical damage, 
which act in the endoplasmic network, mitochondria, plasmatic membrane, peroxisomes and cytosol, 
as well as extracellular ambient. The first mechanism is the prevention of production or the rapid 
inactivation of free radicals, thanks to the action of enzymes, like catalase, peroxidase glutathion 
complex and superoxydedismutase (SOD), or of transition-metals binding proteins, like transferrin, 
ferritin and ceruloplasmin. The second mechanism interrupts propagation of the lipid peroxidation 
chain by inactivating the intermediate radicals. This mechanism is carried out by molecules called 
“scavengers”, which can be water-soluble, such as albumin, bilirubin, ascorbic acid, urates and thiols, 
or liposoluble, e.g., vitamin E and CoQ10, the only liposoluble antioxidant synthesized in living 
organisms. The mobility of scavengers, particularly the liposoluble ones and, most especially at the 
membrane level, allows interception of radicals and transforms them into more stable molecules and 
therefore stops damaging the chain. Sometimes scavengers can be regenerated, that is the case of 
CoQ10. The third defensive mechanism uses processes which remove molecules damaged by oxidative 
attack, allowing the reconstitution of normal structures; for instance, specific phospholypases remove 
the peroxidized fatty acids, enabling the re-acylation of damaged molecules by an acyl-CoA and the 
respective enzyme [12]. 
3. Clinical Significance of CoQ10 Measurement 
The clinical value of CoQ10 is clear with respect to the antioxidant protection of lipoproteins. In fact, 
circulating LDLs are particularly prone to oxidative damage with generation of cytotoxic products, 
associated with atherosclerosis [13]. In LDLs, CoQ10 is oxidized before vitamin E, and the appearance Int. J. Mol. Sci. 2011, 12 9220 
 
 
of fat acids hydroperoxides occurs only after ubiquinol depletion [14], indicating CoQ10 as a first-line 
barrier against oxidative stress. Moreover, the treatment per os with exogenous CoQ10 in normal 
subjects induces an increase of ubiquinol levels in plasma and lipoproteins and an augmented 
resistance to LDL peroxidation [15]. Oxidative stress, obesity, metabolic syndrome and insulin resistance 
are crucial elements in the pathogenesis of atherosclerosis and cardiovascular disease, because of the 
association with lipoproteins rich in triglycerides (small and dense LDLs), oxidized LDLs, antibodies 
anti-oxidized LDLs and other oxidized and glycated particles, F2-isoprostans, soluble adhesion 
molecules, augmented levels of fibrinogen and PAI-1 e low levels of t-PA, an increase in CRP, IL-6, 
AA, omocistein, advanced glycation products [16–18]. Dealing with diabetes, blood plasma and 
cellular antioxidant defense is often reduced [19], and also CoQ10 plasma levels were found to be 
decreased in diabetic patients [20]. So we understand why lipoproteins isolated by diabetic subjects are 
more susceptible to the oxidation process. 
The significance of oxidative stress in coronary cardiopathy has been investigated in a case-control 
study [21] and in two important cohort studies, the “Nurses’ Health Study” [22] and the   
“Physicians’ Health Study” [23]. The positive effect of the treatment with CoQ10 on angina pectoris, 
total arrhythmias, and left ventricular function after myocardial infarction was shown in the short  
term [24], as well as the long-term prognosis [25]. In conclusion, there is a relationship between low 
concentrations of plasma CoQ10 and coronary disease, even if this correlation is not so strong as even 
to be considered a casual relation [26]. However, ubiquinol/ubiquinone ratio is considered an oxidative 
stress marker in coronary disease and LDL/CoQ10 ratio was proposed as an index of coronary   
risk factor [20]. 
There are a lot of medical investigations concerning the potential therapeutic usefulness of CoQ10 in 
the treatment of various diseases, including endocrine ones: cardiovascular, neurological, muscular, 
immunologic, dental, diabetes, male infertility [3,27]. 
4. CoQ10 and Thyroid 
Both hyperthyroidism and hypothyroidism are associated with enhanced oxidative stress involving 
enzymatic and non-enzymatic antioxidants [28]. In particular, hyperthyroidism is associated with 
reduced circulating levels of α-tocopherol [29,30] and CoQ10 [31,32], and some complications of 
hyperthyroidism are due to oxidative stress in target tissues [33]. Increasing CoQ10 values were found 
when going from hyper- to hypo-thyroidism, with euthyroism in the middle [34], and in a previous 
study we showed a significant inverse correlation between thyroid hormones and plasma CoQ10 [35]. 
This correlation was further confirmed in other studies and in a larger group of patients [32], and could 
cover diagnostic usefulness in those clinical conditions characterized by uncoupling of thyroid hormone 
levels and metabolic status, like amiodarone-induced thyroid dysfunction [35] and inappropriate   
thyroid stimulating hormone secretion. 
Values of CoQ10 in hyperthyroid patients are among the lowest reported in different human diseases 
(Table 1). The reasons for this phenomenon include: decreased synthesis related to competition for 
tyrosine, which is a common substrate for CoQ10 and thyroxin synthesis (but this hypothesis was 
disconfirmed by experimental data in animals; increased CoQ10 utilization, due to the increased 
metabolic demand; increased degradation; decreased levels of carriers in serum, since it is Int. J. Mol. Sci. 2011, 12 9221 
 
 
demonstrated that release of very-low-density lipoproteins from liver is decreased in hyperthyroidism. 
Symmetrical mechanisms can be invoked to explain high CoQ10 levels in hypothyroid patients.  
Table 1. Effect of thyroid function and other hormonal disorders, alone and combined with 
hypothyroidism, on CoQ10 plasma levels (values are mean ± SEM). 
 
Patients
(No) 
CoQ10 
(μg/mL) 
CoQ10/Chol. 
(nmol/mmol) 
Ref. 
Control subjects  21  0.68 ± 0.04  217.2 ± 20.3 
32  Hyperthyroidism  25  0.45 ± 0.03  167.0 ± 20.5 
Hypothyroidism  27  1.04 ± 0.07  211.1 ± 11.2 
Hypoadrenalism  19  0.67 ± 0.06  188.1 ± 10.2 
39 
Hypoadrenalism & Hypothyroidism 19  0.92 ± 0.07  231.6 ± 32.4 
Hypogonadism  10  0.66 ± 0.06  190.8 ± 13.0 
40 
Hypogonadism & Hypothyroidism  6  1.11 ± 0.02  216.0 ± 25.0 
Acromegaly  10  0.50 ± 0.02  122.6 ± 11.6 
41 
Acromegaly & Hypothyroidism  4  0.98 ± 0.05  202.2 ± 15.3 
In patients who underwent total thyroidectomy for papillary carcinoma or multinodular goiter, we 
found that patients with non toxic multinodular goiter exhibited low CoQ10 values in pathological areas, 
probably related to colloid accumulation; on the contrary, in active proliferating tissues (toxic goiter or 
neoplasm) CoQ10 concentrations were greater than in unaffected areas [32]. These data pointed toward 
increased CoQ10 uptake related to increased metabolic demand. Pharmacological treatment with 
metimazole, restoring normal values of thyroid hormones, also normalizes CoQ10 values (Figure 3), as 
seen in hyperthyroidal children too, even after CoQ10 was adjusted to cholesterol concentration, 
confirming a lipid-independent effect (apart from a decreased carrier capacity in serum) of the 
hyperthyroid state on the CoQ10 levels [5,36]. 
Figure 3. Effect of thyrostatic therapy on CoQ10 levels. Adapted with permission from [5]. 
 
More recently, we tested a group of patients with low-T3 syndrome due to chronic obstructive 
pulmonary disease: again CoQ10 was higher than patients with the same disease and normal T3 levels, 
suggesting that real hypothyroidism could be present in such situation [37]. Int. J. Mol. Sci. 2011, 12 9222 
 
 
5. CoQ10 in Other Endocrine Diseases 
5.1. Adrenal Disease 
Due to the importance of oxidative stress in the pathophysiology of adrenal gland, we performed 
studies evaluating both blood plasma Total antioxidant capacity (TAC) and CoQ10. A further rationale 
for studying CoQ10 in pituitary-adrenal disease was the common biosynthetic pathway of cholesterol 
and ubiquinone. CoQ10 levels were significantly lower in isolated hypoadrenalism than in patients with 
adrenal hyperplasia and multiple pituitary deficiencies [38]. These preliminary data indicate that 
secretion of adrenal hormones is in some way related to CoQ10 levels, both in augmented and reduced 
conditions. However in secondary hypoadrenalism, some other pituitary dependent axes can be 
affected. Therefore we compared patients with post-surgical isolated hypoadrenalism with those who 
also presented hypothyroidism. Since thyroid hormones play an important role in modulating CoQ10 
levels and metabolism, when coexistent (Table 1), thyroid deficiency seems to play a prevalent role 
instead of adrenal deficiency [39]. 
5.2. Gonadal Disease 
To investigate the role of gonadal steroids in systemic antioxidant regulation, we determined 
plasma CoQ10 and its contribution to TAC in post-surgical hypopituitaric patients. Sixteen out of 26 
patients presented low testosterone values and were also studied after treatment with testosterone 
enantate. CoQ10 levels were significantly lower in isolated hypogonadism than in normogonadism. 
Testosterone treatment induced a significant change both in CoQ10 level and TAC. CoQ10 and TAC 
values significantly correlated, suggesting an inter-relationship between different antioxidants [40]. 
Our data suggest that hypogonadism could represent a condition of oxidative stress, in turn related 
with augmented cardiovascular risk. Once again, when hypogonadism was associated to 
hypothyroidism, the effect of the latter was prevalent (Table 1). 
5.3. Growth Hormone 
A previous study of our group also evaluated acromegalic patients [41], harboring a GH-secreting 
pituitary adenoma. In this case, we observed lower CoQ10 values; however sometimes the pituitary 
adenoma can damage other pituitary cell lines or disrupt the connection with hypothalamus, causing 
defects in other pituitary dependent axes (thyroid, adrenal, gonadal). In the case of secondary 
hypothyroidism, as seen above, this last phenomenon can be prevalent; therefore in acromegalic 
patients with concomitant hypothyroidism, CoQ10 plasma levels are increased (Table 1). Growth 
hormone probably influences CoQ10 consumption, due to accelerated metabolism, as in the case   
of hyperthyroidism. 
6. Conclusions 
Antioxidant systems represent a key defense mechanism in our body and an unbalance of these 
systems can underly a wide spectrum of human disease. The reported experimental data show that 
systemic hormones can affect their levels, both in physiological and pathological conditions. However Int. J. Mol. Sci. 2011, 12 9223 
 
 
CoQ10 can be affected by different mechanisms; its low levels in plasma, in fact, can be due to 
accelerated metabolism and/or consumption, such as in hyperthyroidism and acromegaly, or a reduced 
synthesis, such as in hypoadrenalism and hypogonadism (Figure 2). 
All pituitary hormones and the dependent glands (thyroid, adrenal, gonads) are involved, even if an 
unequivocal picture is far from being designed. However, it seems clear that in all the considered 
conditions, the effect of thyroid hormones is predominant on other hormones in influencing CoQ10 
plasma levels. Even though more controlled studies are needed, the clinical usefulness of CoQ10 
determination for a diagnosis refinement, or CoQ10 oral supplementation as a support to the specific 
endocrine therapy, has already been demonstrated in many cases.  
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